February 15, 2019 10:12 AM ESTUpdated 10:28 AM
Peer Review

J&J R&D vet Pe­ter Tum­mi­no joins the Big Phar­ma ex­o­dus, leap­ing to Nim­bus as CSO; Ca­dent taps Jodie Mor­ri­son for CEO

Amber Tong

→ Af­ter spend­ing the last 16 years as a re­searcher in Big Phar­ma, Pe­ter Tum­mi­no is go­ing biotech.

Nim­bus re­ports that Tum­mi­no is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe­si­ty

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times